First Nasal Vaccine Developed by Bharat Biotech supported by DBT-BIRAC gets nod of regulator for Phase 2 Trial -ForumIAS Blog

ForumIAS LATEST

1. 1. SFG FRC 2027 | Program starts from 19th Dec. 2026 | Admissions open for Entrance Test Click Here to know more →
  2. Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
  3. [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
  4. 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →

Source: PIB

BBV154, the first Nasal Vaccine against Covid-19 has received the regulator’s nod for conducting Phase 2 and 3 clinical trials.

BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.
It is the first Intranasal Covid-19 Vaccine being developed by Bharat Biotech.

Mission COVID Suraksha was launched to reinforce and accelerate COVID-19 vaccine development efforts as part of the third stimulus package, Atmanirbhar 3.0.
Aim: To consolidate and streamline available resources towards a warpath for accelerated vaccine development in order to bring a safe, efficacious, affordable and accessible COVID-19 Vaccine to the citizens at the earliest with a focus on Atma Nirbhar Bharat.
Implemented by: The mission is led by the Department of Biotechnology (DBT) and implemented by a dedicated Mission Implementation Unit at the Biotechnology Industry Research Assistance Council(BIRAC).

BIRAC is a not-for-profit Section 8, Public Sector Enterprise set up by DBT.
Mandate: It has been set up as an Interface Agency to strengthen and empower the emerging biotech enterprises to undertake strategic research and innovation for globally competitive product development to address unmet needs.